Danaher Corporation Q2 2026 Financial Results; Strategic Capital Allocation, and Market Valuation Dynamics
Danaher Corporation (NYSE: DHR) reported strong second-quarter 2026 financial results, generating revenue of $6.265 billion (+5.5% YoY) and non-GAAP adjusted diluted earnings per share (EPS) of $1.94 (+8.0% YoY), with both key metrics outperforming Wall Street consensus estimates. Non-GAAP core sales grew 3.0% overall and 4.5% when excluding post-pandemic respiratory testing normalizations, driven by a rebound across Life Sciences workflows and continued adoption of clinical diagnostics menus.
